BVF as of Sept. 30, 2024
Portfolio Holdings for BVF
BVF holds 55 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 32.1 | $1.1B | 22M | 50.42 | |
| Kymera Therapeutics (KYMR) | 7.1 | $244M | 5.2M | 47.33 | |
| Revolution Medicines (RVMD) | 4.6 | $158M | 3.5M | 45.35 | |
| Mirum Pharmaceuticals (MIRM) | 3.5 | $120M | 3.1M | 39.00 | |
| Tyra Biosciences (TYRA) | 3.2 | $110M | 4.7M | 23.51 | |
| Olema Pharmaceuticals (OLMA) | 3.2 | $109M | 9.1M | 11.94 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 2.9 | $98M | 2.2M | 43.89 | |
| Cullinan Oncology (CGEM) | 2.8 | $96M | 5.8M | 16.74 | |
| Xoma Royalty Corporation Com New (XOMA) | 2.8 | $96M | 3.6M | 26.48 | |
| Axsome Therapeutics (AXSM) | 2.7 | $94M | 1.0M | 89.87 | |
| Protagonist Therapeutics (PTGX) | 2.4 | $83M | 1.9M | 45.00 | |
| 4d Molecular Therapeutics In (FDMT) | 2.3 | $80M | 7.4M | 10.81 | |
| Ac Immune Sa SHS (ACIU) | 2.2 | $74M | 20M | 3.78 | |
| Gh Research Ordinary Shares (GHRS) | 2.0 | $70M | 10M | 6.69 | |
| Kura Oncology (KURA) | 1.9 | $66M | 3.4M | 19.54 | |
| Third Harmonic Bio (THRD) | 1.7 | $59M | 4.4M | 13.55 | |
| Ionis Pharmaceuticals (IONS) | 1.7 | $58M | 1.5M | 40.06 | |
| Zymeworks Del (ZYME) | 1.7 | $58M | 4.6M | 12.55 | |
| Essa Pharma Com New (EPIX) | 1.6 | $53M | 8.7M | 6.06 | |
| Agios Pharmaceuticals (AGIO) | 1.5 | $53M | 1.2M | 44.43 | |
| Celcuity (CELC) | 1.5 | $52M | 3.5M | 14.91 | |
| 89bio (ETNB) | 1.5 | $50M | 6.8M | 7.40 | |
| Foghorn Therapeutics (FHTX) | 1.4 | $49M | 5.3M | 9.31 | |
| Galapagos Nv Spon Adr (GLPG) | 1.3 | $45M | 1.6M | 28.79 | |
| Ideaya Biosciences (IDYA) | 1.3 | $45M | 1.4M | 31.68 | |
| Annexon (ANNX) | 1.2 | $41M | 7.0M | 5.92 | |
| Cg Oncology (CGON) | 1.1 | $38M | 995k | 37.73 | |
| Repare Therapeutics Ord (RPTX) | 1.0 | $36M | 10M | 3.44 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.7 | $25M | 1.5M | 16.60 | |
| Xencor (XNCR) | 0.5 | $17M | 850k | 20.11 | |
| Eledon Pharmaceuticals (ELDN) | 0.5 | $16M | 6.3M | 2.49 | |
| Tscan Therapeutics (TCRX) | 0.4 | $15M | 3.0M | 4.98 | |
| Engene Holdings (ENGN) | 0.4 | $15M | 2.3M | 6.60 | |
| Immunic (IMUX) | 0.4 | $15M | 8.9M | 1.65 | |
| Allakos | 0.3 | $11M | 17M | 0.65 | |
| Avalo Therapeutics Com New (AVTX) | 0.3 | $9.1M | 967k | 9.46 | |
| Ikena Oncology (IKNA) | 0.2 | $8.3M | 4.8M | 1.73 | |
| Cidara Therapeutics Com New (CDTX) | 0.2 | $7.6M | 703k | 10.75 | |
| Cytomx Therapeutics (CTMX) | 0.2 | $6.2M | 5.2M | 1.18 | |
| Vigil Neuroscience (VIGL) | 0.2 | $6.2M | 1.8M | 3.40 | |
| Vistagen Therapeutics Ord (VTGN) | 0.2 | $6.0M | 2.0M | 3.01 | |
| Verastem Com New (VSTM) | 0.1 | $5.0M | 1.7M | 2.99 | |
| Ovid Therapeutics (OVID) | 0.1 | $4.5M | 3.9M | 1.18 | |
| Pieris Pharmaceuticals Com New | 0.1 | $4.3M | 258k | 16.74 | |
| Verve Therapeutics (VERV) | 0.1 | $3.1M | 650k | 4.84 | |
| Sab Biotherapeutics Com New (SABS) | 0.1 | $2.5M | 918k | 2.70 | |
| Molecular Partners Ads (MOLN) | 0.1 | $2.1M | 443k | 4.82 | |
| Elevation Oncology (ELEV) | 0.1 | $1.8M | 3.0M | 0.60 | |
| Glycomimetics | 0.0 | $1.6M | 9.5M | 0.17 | |
| Inventiva Sa Ads (IVA) | 0.0 | $1.3M | 686k | 1.85 | |
| Tenax Therapeutics Com New (TENX) | 0.0 | $1.2M | 340k | 3.46 | |
| Engene Holdings *w Exp 10/31/202 (ENGNW) | 0.0 | $804k | 945k | 0.85 | |
| Molecular Templates Com New (MTEMQ) | 0.0 | $734k | 522k | 1.41 | |
| Nls Pharmaceutics Com New (NLSP) | 0.0 | $728k | 144k | 5.07 | |
| Forte Biosciences Com New (FBRX) | 0.0 | $668k | 119k | 5.60 |
